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Abstract
Hunteria umbellata (K. Schum.) Hallier f. (family: Apocynaceae) is reputed for the folkloric
management of labour, pain and swellings, stomach ulcers, diabetes, obesity, and anaemia, with no scientific
report of its toxicity and reversibility profile. The present study was, therefore, aimed at investigating the in vivo
toxicity and reversibility profile of the aqueous seed extract of Hunteria umbellata (HU). The acute oral and
intraperitoneal toxicity studies of HU were determined in Swiss albino mice while its 90-day oral toxicity and
toxicity reversibility profile on anthropometric, biochemical, haematological and histopathological parameters
were also assessed using standard procedures. Results showed that the LD50 values for the acute oral and
intraperitoneal toxicity studies for HU were estimated to be 1000 mg/kg and 459.3 mg/kg, respectively. Visible
signs of immediate and delayed toxicities including starry hair coat, respiratory distress, and dyskinesia were
observed. For the chronic oral toxicity study, HU administered for 90 days produced significant (p<0.001)
reductions in the weight gain pattern and significant (p<0.001) and dose related increases in the relative weights
of liver, stomach, spleen, testis, lungs and heart, at the 100 and 500 mg/kg of HU. Chronic HU treatment also
produced significant (p<0.05, p<0.001) dose related reductions in the serum levels of fasting blood glucose,
bicarbonate, urea and creatinine while causing non-significant (p>0.05) alterations in the serum levels of sodium,
potassium, alaninine transaminase, aspartate transaminase, alkaline phosphatase, total and conjugated bilirubin,
total protein and albumin. Also, chronic oral treatment with HU produced significant (p<0.05, p<0.01, p<0.001)
and dose-related increases in the red cell count, packed cell volume, haemoglobin concentration, platelet count,
total leucocyte count and lymphocyte differential while producing significant (p<0.05) reductions in neutrophil
and granulocyte differentials. HU also produced histological features of proliferations of the stomach epithelia,
lung tissues, splenic white and red pulps, and testicular spermatogenic series. Following 14 days of oral toxicity
reversibility test, there was no significant (p>0.05) reversal in the serum levels of the biochemical and
haematological parameters investigated, including the HU-induced histological lesions.
Overall, results of this study showed that HU has a relatively low oral toxicity profile but its prolonged
use, particularly, at high doses should be with great caution.
Key words: Hunteria umbellata, Toxicity and reversibility profile, Haematology, Liver and Renal function tests;
Histopathology, Rodents.
Introduction
Hunteria umbellata (K. Schum.) Hallier f. (Apocynaceae) is a medicinal plant with a long standing use
in the treatment of various ailments in Nigeria and Ghana (Adegoke and Alo, 1986). Also, the use of the plant in
herbal medicines has long been reported (Bevan et al., 1967). Among the Yoruba and Binis (Southwest Nigeria),
it is locally known as “Abeere”.
In African folk medicine, various extracts prepared from different parts of the plant Hunteria umbellata
(K. Schum.) Hallier f. are employed in the treatment of various human diseases such as sexually transmitted
infections including yaws, stomach ulcers, pains and swellings, diabetes mellitus, dysmenorrhoea and to induce
or augment labour (Adegoke and Alo, 1986; Falodun et al., 2006). Water decoction made from the dried seeds of
Hunteria umbellata (K. Schum.) Hallier f. is highly valued in the local management of diabetes mellitus, obesity,
stomach ache, pains and swellings, hypertension and as immune booster (Boone, 2006; Adeneye and Adeyemi,
2009a). Recently, Falodun et al. (2006) and Igbe et al. (2009) reported the oxytocic effect of the leaf aqueous
extract and antipyretic and analgesic effect of the fresh fruit pulp of Hunteria umbellata, respectively. The oral
Adeneye et al., Afr J Tradit Complement Altern Med. (2010) 7(4):350-369 351
hypoglycaemic effect of the aqueous seed extract of Hunteria umbellata (K. Schum.) Hallier f. (HU) in various
in vivo models of experimental diabetes was also recently reported (Adeneye and Adeyemi, 2009a; 2009b). In
addition, the anti-obesity and hyperlipidaemic activities of HU have also been reported to be mediated via
inhibitions of intestinal lipid absorption and de novo cholesterol and triglyceride syntheses (Adeneye et al,
2010).
Despite its wide application in human health, the folkloric therapeutic efficacy and the safety profile of
the seed extract are yet to be scientifically validated. Therefore, the current study was designed to evaluate both
the toxicity and reversibility profile of HU in rodents, which is strongly in line with the World Health
Organization set goals on determining the safety profile of any medicinal plants before it can become acceptable
for human use.
Materials and methods
Collection of plant materials
Plant collection, identification and authentication were made as previously described by Adeneye and
Adeyemi (2009a).
Cold aqueous extraction
In the preparation of the cold aqueous extract of the seeds of Hunteria umbellata (K. Schum.) Hallier f.,
100 g of the dry seeds was pulverized to white-to-light brown fine powder using domestic blender. Thirty grams
of the fine powdered sample was dissolved in 500 ml of distilled water in a 1 litre Pyrex beaker and was left to
stand in the refrigerator at -4 ºC for 72 h. After 72 h, the homogenate was then rigorously shaken intermittently
for 6 hours and was rapidly filtered through a piece of clean white cloth. The filtrate was then transferred to an
aerated oven preset at 40 ºC and completely dried until a deep brown, aromatic solid residue was obtained. The
weight of the solid residue left behind was 23 g, giving a yield of 76.67% (w/w). This procedure was repeated for
three more times. The residues, thus obtained, were pooled, and stored in air- and moisture-tight container which
was kept in a refrigerator maintained at -4 ºC. From this, a fresh stock was reconstituted in distilled water at a
concentration of 100 mg/ml (pH = 4.96), whenever needed.
Experimental animals and their care
Young adult white albino rats and Swiss albino mice (aged 8-14 weeks old) that were used in this study
were obtained from the Animal House of the Lagos State University College of Medicine, Ikeja, Lagos State,
Nigeria, after ethical approval was obtained. The rats were handled in accordance with international principles
guiding the Use and Handling of experimental animals (United States National Institutes for Health, 1985). The
rats were maintained on standard rat feed (Ladokun Feeds, Ibadan, Nigeria) and water which were made
available ad libitum. The rats were maintained at an ambient temperature between 28-30 ºC, humidity of 55 ±
5%, and standard (natural) photoperiod of approximately 12 hour of light (06:30 h – 18:30 h) alternating with
approximately 12 hour of darkness (18:30 h - 06:30 h).
Acute oral toxicity study of HU using Miller and Tainter method
Overnight fasted Swiss albino mice were randomly divided into eight groups with six mice in each
group such that the differences within and between groups do not exceed ±20% of the average weight of the
sample size. Group I mice served as the untreated control and were orally administered with 10 ml/kg of distilled
water while Groups II-VIII mice were orally gavaged 125, 250, 500, 750, 1500, 1750 and 2000 mg/kg of the
aqueous seed extract of Hunteria umbellata, respectively. The animals were closely monitored for behavioural
and general signs of toxicity such as feeding and drinking pattern, restlessness, and mortality, etc. within the first
24 hrs. The median lethal dose (LD50) was estimated by log-dose probit analysis of Miller and Tainter (1944)
and as adopted by Agbaje et al. (2009). Surviving mice were further observed for 14 days for delayed toxicities
or death.
Acute intraperitoneal toxicity studies of HU
Using the method of Miller and Tainter (1944) described for the acute oral toxicity, overnight fasted
mice were randomly divided into five treatment groups (Groups II-VI) and given 62.5, 125, 250, 500, 750 and
1500 mg/kg of the HU intraperitoneally. In addition, mice in the untreated control (Group I) were given 1 ml/kg
of distilled water intraperitoneally.
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Chronic oral toxicity of HU
A total of 96 white albino Wistar rats, 6-8 weeks old and of either sex were randomly allotted to 4
groups of 12 rats of per sex per group and such that the difference within and between groups do not exceed ±
20% of the average weight of the sample size. In either sex of rats, Group I rats served as the untreated control
and were orally administered with 10 ml/kg of distilled water while Groups II-IV rats were orally treated with
single, daily doses of 20 mg/kg body weight (a-fifth of the pharmacologically active dose), 100 mg/kg
(pharmacologically active dose), and 500 mg/kg (5 folds the pharmacologically active dose) (Tanira et al., 1988;
Thanarbon et al., 2006) of HU, respectively, for 90 days. The rats were closely observed for the general and
behavioural signs of toxicity, body weight changes and mortality. At the end of the 90-day treatment period, 6
rats from each group of treated rats of either sex were randomly anaesthetized with inhaled diethyl ether and
blood samples were withdrawn directly from the heart chamber with 21 G needle mounted on a 5 ml syringe
plunger (Unique Pharmaceuticals, Sango-Otta, Ogun State, Nigeria). After the samples were collected into the
sample bottles, the animals were sacrificed humanely and selected internal organs such as the liver, heart,
kidneys, spleen, stomach, and testes were collected. The blood and selected organs were processed for
biochemical, haematological and histopathological studies.
Oral toxicity reversibility test of HU
After the initial sacrifice, the remain six rats per sex of the experimental animal from each treatment
group were left untreated with the extract but given drinking potable water and allowed free access to feed for
additional 2 weeks before they were also sacrificed humanely using same procedure described earlier.
Effect of HU on body weight in rats
In the course of the 90-day oral treatment, body weights of rats were regularly taken at 2 weeks interval
with electronic Mettler weighing balance (Mettler Toledo Type BD6000, Mettler-Toledo GmbH, Greifensee,
Switzerland). Absolute and percentage (%) weight changes were calculated in respect of the initial body weight
on day 1.
Effect of HU on relative weights of selected vital internal organs
Rat internal organs including heart, lungs, liver, spleen, kidneys, stomach, and testis were carefully
dissected out and freed from adjoining supporting connective tissues. The organs were gently rinsed in normal
saline, blotted with filter paper (Whatmann’s No. 1 filter paper) and weighed. Each weighed organ was grossly
observed for visible lesions and thereafter standardized for 100 g body weight for the corresponding animal
weight (Yemitan and Adeyemi, 2004).
Haematological assessment
Blood samples were collected directly from the heart chamber from anaesthetized rats with 12 G needle
mounted on a 5 ml syringe plunger (Unique Pharmaceuticals, Sango-Otta, Ogun State, Nigeria). Blood collection
into EDTA-coated sample bottles (BD Vacutainer®, BD-Plymouth, Plymouth, U.K.) was for determination of
red cell count (RBC), packed cell volume (PCV), haemoglobin concentration (Hb), platelet count (PLT),
erythrocyte indices, total white blood cell counts and its differentials using Automated Haematology System
(Sysmex Haematology-Coagulation Systems®, Model KX-21N, Sysmex Incorporation, Kobe, Japan).
Biochemical assays
The blood samples drawn directly from the heart chamber were collected into non-heparinised and
allowed to clot and then centrifuged at 5000 rpm to separate clear sera from the clotted blood samples. The clear
samples were obtained for assays of the following biochemical parameters: alanine aminotransferase (ALT),
aspartate aminotransferase (AST), alkaline phosphatase (ALP), fasting blood glucose (FBG), urea, creatinine,
total protein, albumin, triglyceride, total cholesterol and cholesterol fractions [high density lipoprotein
cholesterol (HDL-c), low density lipoprotein cholesterol (LDL-c), and very low density lipoprotein cholesterol
(VLDL-c)], total (TB) and conjugated bilirubin (CB). Serum ALT, AST and ALP were measured using the
enzyme kinetic method of Reitman and Frankel (1957). The readings were done at 546 nm for ALT and AST
and 590 nm for ALP. One unit of ALT and AST activities were defined as the amount of protein that liberated
one μmole pyruvate/ml per min and one μmole oxaloacetate/ml per min, respectively, under experimental 
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condition Urea was measured using modified diacetylmonoamine method, read at 546 nm (Marsh, 1965). Other
biochemical determinations include triglyceride, total cholesterol and cholesterol fractions using method of
Fossati and Principe (1982), while glucose was estimated using modified oxidase method of Trinder (1969).
Estimation of creatinine was done by the Jaffe’s reaction method (Biod and Sirota, 1948; Owen et al., 1954;
Chawla, 1999). The total protein was estimated by Biuret method (Treitz, 1970) while that of albumin was
determined by bromocresol green (Lowry et al., 1957). The total bilirubin and the conjugated bilirubin were
determined by Jendrassik–Grof method (Spencer and Price, 1977). In addition, serum concentrations of sodium,
potassium, and bicarbonate were estimated using standard procedures.
Histopathological studies
After the animals were sacrificed, postmortem examination was performed on the six randomly selected
rats from each treatment and control groups with their vital organs identified and carefully dissected out en bloc
for histopathological examinations. After rinsing in normal saline, the organs were preserved in 10% formo-
saline before they were completely dehydrated in absolute (100%) ethanol. The organs were then embedded in
routine paraffin blocks. From the embedded paraffin blocks, 4-5 μm thick sections of each tissue was prepared 
and stained with haematoxylin-eosin. These were examined under a photomicroscope (Model N-400ME, CEL-
TECH Diagnostics, Hamburg, Germany) connected with a host computer. Sections were illuminated with white
light from a 12V halogen lamp (100 W) after filtering with a 520nm monochromatic filter. The slides were
examined for associated histopathological lesions (Thanarbon et al., 2006).
Statistical Analysis
Results were presented as mean ± S.D. for body weights, organ weights and relative organ weights
while data for haematological and, biochemical indices were expressed as mean ± S.E.M. of six observations.
Statistical analysis was done using two-way analysis of variance followed by post-hoc test, Student-Newman-
Keuls test on SYSTAT 10.6. Statistical significance were considered at p<0.05, p<0.01, and p<0.001.
Results
Acute toxicity studies
The results of the acute oral and intraperitoneal toxicity tests of HU using the Miller and Tainter (1944)
are shown in Figures 1 and 2, respectively. Treatment with HU did not cause mortality for up to 125 mg/kg
body weight but increasing mortality was recorded with increasing doses of 250, 500, 750, 1500, 1750 and 2000
mg/kg body weight orally. However, at 2000 mg/kg body weight orally and 1500 mg/kg body weight
intraperitoneally, 100% mortality was recorded. Death in each case was preceded by peri-oral tremor, followed
by decreased locomotor activity and generalized tonic-clonic contraction and asphyxia. Similar pattern of
behavioural toxicity was recorded in the acute intraperitoneal toxicity determination in rats given the test doses
of 62.5, 125, 250, 500, 750 and 1500 mg/kg body weight.
Chronic oral toxicity studies
Effect of 90-days oral treatment with 20-500 mg/kg/day of HU on body weight of treated rats
Chronic treatment with 20-500 mg/kg/day caused significant (p<0.001) reductions in the pattern of
weight gain in the 100 and 500 mg/kg of HU-treated rats when compared to the control values. Reductions in the
weight gain pattern became noticeable from the 30th day to the 91st day of treatment in the male rats (Table 1a)
while it became noticeable only from 60th day to the 91st day in the female rats (Table 1b). However, there were
no significant (p>0.05) differences between the 20 mg/kg/day of HU-treated and the control rats (Tables 1a and
1b)
Effect of 14-day toxicity reversibility of HU on body weight of treated rats
On withdrawing HU treatment, there was reversal in the pattern of weight gain in the rats such that
pattern of weight gain in the 20 mg/kg of HU-treated rats was not significantly (p>0.05) different from those of
the control group (Tables 1a and 1b). However, the pattern of weight gain in 100 and 500 mg/kg of HU-treated
rats was still significantly (p<0.05) lower than those of control and 20 mg/kg of HU-treated rats (Tables 1a and
1b).
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Table 1a: Effect of chronic oral treatment with HU and toxicity reversibility on body weights of treated male
rats
___________________________________________________________________________________
Treatment day I II III IV
___________________________________________________________________________________
1st 111.8 ± 51.7 118.6 ± 49.1 106.4 ± 45.3 112.1 ± 71.3
15th 116.3 ± 57.5 159.3 ± 52.0 130.3 ± 43.5 158.6 ± 75.1
30th 213.9 ± 55.8 201.7 ± 46.5 124.1 ± 39.0f 149.9 ± 58.3f
45th 247.4 ± 52.0 224.6 ± 42.5 171.3 ± 31.4f 188.3 ± 48.0f
60th 271.2 ± 37.4 282.5 ± 27.9 183.7 ± 27.1f 189.5 ± 56.0f
75th 282.5 ± 50.6 282.5 ± 29.7 199.8 ± 25.1f 217.3 ± 47.7f
91st 310.8 ± 30.7 301.8 ± 28.8 196.4 ± 26.0f 190.6 ± 48.4f
Reversibility
15th day 385.0 ± 28.7 328.3 ± 27.7 270.7 ± 34.8d 251.0 ± 61.7d
___________________________________________________________________________________
f represents a significant reduction at p<0.001 when compared to the Group I (control) values
Group I = 10 ml/kg/day of distilled water, Group II = 20 mg/kg/day of HU, Group III = 100 mg/kg/day of HU
Group IV = 500 mg/kg/day of HU.
Table 1b: Effect of chronic oral treatment with HU and toxicity reversibility on body weights of treated female
rats
___________________________________________________________________________________
Treatment day I II III IV
___________________________________________________________________________________
1st 107.8 ± 38.0 118.2 ± 39.3 124.6 ± 27.7 117.4 ± 36.6
15th 133.9 ± 31.6 160.5 ± 36.6 166.8 ± 19.0 152.7 ± 30.2
30th 175.5 ± 31.4 190.9 ± 34.9 182.4 ± 13.8 159.5 ± 45.3
45th 202.3 ± 37.6 186.9 ± 36.4 202.3 ± 18.8 183.4 ± 38.1
60th 231.0 ± 40.2 187.5 ± 21.5e 205.1 ± 19.5e 187.8 ± 37.0f
75th 258.9 ± 50.0 202.3 ± 24.3e 212.1 ± 17.4e 189.9 ± 33.8f
91st 293.6 ± 47.7 231.0 ± 26.5e 210.6 ± 13.4e 184.9 ± 27.9f
Reversibility
15th day 299.7 ± 7.5 294.0 ± 13.2 277.0 ± 24.6 252.0 ± 17.9d
___________________________________________________________________________________
d, e and f represent significant reductions at p<0.05, p<0.01 and p<0.001, respectively, when compared to the Group I (control)
values. Group I = 10 ml/kg/day of distilled water, Group II = 20 mg/kg/day of HU, Group III = 100 mg/kg/day of HU,
Group IV = 500 mg/kg/day of HU’
Table 2a: Effect of chronic oral treatment with HU on the relative organ weight of some selected vital body
organs of male rats
___________________________________________________________________________
I II III IV
___________________________________________________________________________________
Liver 2.7 ± 0.3 2.8 ± 0.3 3.4 ± 0.6c 3.8 ± 0.2c
Stomach 0.5 ± 0.1 0.9 ± 0.1b 1.0 ± 0.2c 1.1 ± 0.3c
Lungs 0.7 ± 0.1 0.4 ± 0.2 0.9 ± 0.2c 1.1 ± 0.2c
Kidneys 0.7 ± 0.1 0.7 ± 0.0 1.0 ± 0.3c 0.5 ± 0.0
Spleen 0.3 ± 0.0 0.3 ± 0.0 0.5 ± 0.1c 0.5 ± 0.0c
Heart 0.3 ± 0.0 0.3 ± 0.0 0.5 ± 0.1c 0.5 ± 0.0c
Testis 2.3 ± 0.2 2.4 ± 0.3 2.5 ± 0.2 2.7 ± 0.3a
___________________________________________________________________________________
a, b and c represent significant increases at p<0.05, p<0.01 and p<0.001, respectively, when compared to control values while d
represents a significant decrease at p<0.05 when compared to compared to Group II values
Group I = 10 ml/kg/day of distilled water, Group II = 20 mg/kg/day of HU, Group III = 100 mg/kg/day of HU
Group IV = 500 mg/kg/day of HU.
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Table 2b: Effect of chronic oral treatment with 20-500 mg/kg/day of HU on the relative organ weight of some
selected vital body organs of female rats
___________________________________________________________________________________
I II III IV
___________________________________________________________________________________
Liver 2.1 ± 0.2 2.9 ± 0.4 2.9 ± 0.3a 3.3 ± 0.4c
Stomach 1.2 ± 0.3 1.0 ± 0.1 0.9 ± 0.2 1.0 ± 0.1
Lungs 0.9 ± 0.0 1.0 ± 0.1 1.0 ± 0.1 1.1 ± 0.3a
Kidneys 0.6 ± 0.2 0.7 ± 0.2 0.3 ± 0.1e 0.4 ± 0.0e
Spleen 0.4 ± 0.0 0.6 ± 0.2a 0.5 ± 0.0 0.5 ± 0.0
Heart 0.4 ± 0.0 0.5 ± 0.1 0.7 ± 0.3 0.5 ± 0.0
___________________________________________________________________________________
a and c represent significant increases at p<0.05 and 0.001, respectively, when compared to control (Group I) values while e
represents a significant decrease at p<0.01 when compared to Group I values.
Group I = 10 ml/kg/day of distilled water, Group II = 20 mg/kg/day of HU, Group III = 100 mg/kg/day of HU,
Group IV = 500 mg/kg/day of HU.
Table 3a: Effect of 14 days of toxicity reversibility test of HU on the relative organ weight of some selected
vital body organs of male rats
___________________________________________________________________________
I II III IV
___________________________________________________________________________________
Liver 2.2 ± 0.1 2.6 ± 0.3 1.8 ± 0.3 2.2 ± 0.8
Stomach 0.7 ± 0.1 0.7 ± 0.2 0.7 ± 0.1 0.7 ± 0.2
Lungs 0.7 ± 0.2 0.7 ± 0.2 0.6 ± 0.1 0.7 ± 0.2
Kidneys 0.5 ± 0.0 0.6 ± 0.1 0.6 ± 0.1 0.6 ± 0.1
Spleen 0.3 ± 0.0 0.3 ± 0.0 0.3 ± 0.0 0.3 ± 0.1
Heart 0.3 ± 0.0 0.3 ± 0.0 0.3 ± 0.0 0.3 ± 0.1
Testis 1.4 ± 0.1 1.6 ± 0.2 1.5 ± 0.3 1.4 ± 0.2
___________________________________________________________________________________
Group I = 10 ml/kg/day of distilled water, Group II = 20 mg/kg/day of HU, Group III = 100 mg/kg/day of HU
Group IV = 500 mg/kg/day of HU.
Table 3b: Effect of 14 days of toxicity reversibility of HU on the relative organ weight of some selected vital
body organs of female rats
______________________________________________________________________ ____________
I II III IV
___________________________________________________________________________________
Liver 2.0 ± 0.0 2.1 ± 0.1 2.4 ± 0.2a 2.1 ± 0.1
Stomach 0.7 ± 0.0 0.7 ± 0.0 0.7 ± 0.1 0.7 ± 0.0
Lungs 0.7 ± 0.0 0.7 ± 0.0 0.7 ± 0.1 0.7 ± 0.0
Kidneys 0.7 ± 0.0 0.7 ± 0.0 0.4 ± 0.0f 0.5 ± 0.2e
Spleen 0.3 ± 0.0 0.3 ± 0.0 0.4 ± 0.0 0.4 ± 0.0
Heart 0.3 ± 0.0 0.3 ± 0.0 0.4 ± 0.0 0.4 ± 0.0
___________________________________________________________________________________
a represents a significant increases at p<0.05 while e and f represent significant decreases at p<0.01 and p<0.001, respectively,
when compared to control (Group I) values. Group I = 10 ml/kg/day of distilled water, Group II = 20 mg/kg/day of HU,
Group III = 100 mg/kg/day of HU, Group IV = 500 mg/kg/day of HU.
Table 4: Effect of chronic HU treatment on the fasting blood glucose (FBG) concentration in the treated rats on
91st day of treatment
Groups Treatment FBG (mg/dl)
(male rats)
FBG (mg/dl)
(female rats)
I 10 ml/kg/day of
distilled water
78.7 ± 0.9 76.5 ± 2.8
II 20 mg/kg/day HU 63.8 ± 1.7d 52.3 ± 2.1d
III 100 mg/kg/day HU 46.8 ± 2.5e 40.0 ± 2.2e
IV 500 mg/kg/day HU 37.0 ± 0.7f 36.2 ± 1.5f
d, e and f represent significant decreases at p<0.05, p<0.01 and p<0.001, respectively, when compared to Group I values
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Table 5: Effect of 14-days reversibility test of HU on the fasting blood glucose (FBG) concentration in male and
female rats
Groups Treatment FBG (mg/dl)
(male rats)
FBG (mg/dl)
(female rats)
I 10 ml/kg/day of
distilled water
59.0 ± 0.7 61.7 ± 1.1
II 20 mg/kg/day HU 60.7 ± 1.7 54.0 ± 3.3
III 100 mg/kg/day HU 47.3 ± 4.0e 49.7 ± 1.7e
IV 500 mg/kg/day HU 38.7 ± 2.0f 42.7 ± 5.1e
e and f represent significant decreases at p<0.01 and p<0.001, respectively, when compared to Group I values
Table 6: Effect of chronic oral treatment with 20-500 mg/kg/day of HU on the serum sodium, potassium,
bicarbonate, urea and creatinine concentrations in male and female rats on 91st day of treatment
___________________________________________________________________________________
Parameters I II III IV
___________________________________________________________________________________
Male rats
Sodium (mEq/L) 139.0 ± 2.6 140.8 ± 2.6 151.3 ± 5.1 145.7 ± 1.5
Potassium (mEq/L) 05.6 ± 0.3 06.2 ± 0.4 06.9 ± 0.5 07.7 ± 0.6
Bicarbonate (mEq/L) 32.3 ± 4.9 28.5 ± 1.7 22.5 ± 1.5d 20.2 ± 1.0d
Urea (mg/dl) 38.0 ± 1.9 37.9 ± 2.1 34.7 ± 1.8 30.7 ± 3.0d
Creatinine (mg/dl) 1.1 ± 0.1 1.1 ± 0.1 0.9 ± 0.1 0.8 ± 0.0d
___________________________________________________________________________________
Female rats
Sodium (mEq/L) 139.0 ± 1.2 143.0 ± 0.7 140.0 ± 0.0 139.0 ± 1.9
Potassium (mEq/L) 06.9 ± 0.3 08.4 ± 0.8 07.3 ± 0.2 08.7 ± 0.9
Bicarbonate (mEq/L) 25.2 ± 3.1 21.8 ± 1.4 21.3 ± 1.7 18.7 ± 1.3d
Urea (mg/dl) 40.9 ± 1.4 33.5 ± 1.9d 30.8 ± 2.2d 28.4 ± 2.2d
Creatinine (mg/dl) 0.8 ± 0.0 0.7 ± 0.0 0.6 ± 0.0d 0.6 ± 0.0d
___________________________________________________________________________________
d represents a significant decrease at p<0.05 when compared to untreated control (Group I) values
Group I = 10 ml/kg/day of distilled water. Group II = 20 mg/kg/day of HU, Group III = 100 mg/kg/day of HU
Group IV = 500 mg/kg/day of HU.
Table 7: Effect of oral toxicity reversibility of HU on the serum sodium, potassium, bicarbonate, urea and
creatinine concentrations in male and female rats
___________________________________________________________________________________
Parameters I II III IV
___________________________________________________________________________________
Male rats
Sodium (mEq/L) 144.0 ± 0.4 143.7 ± 0.4 141.5 ± 1.0 139.8 ± 1.9
Potassium (mEq/L) 07.9 ± 0.1 08.4 ± 0.9 09.0 ± 0.4 08.4 ± 0.9
Bicarbonate (mEq/L) 25.3 ± 1.3 25.7 ± 0.6 25.3 ± 0.8 29.5 ± 0.9a
Urea (mg/dl) 41.4 ± 3.5 30.0 ± 2.2d 25.5 ± 3.8e 23.4 ± 4.2e
Creatinine (mg/dl) 0.8 ± 0.0 0.7 ± 0.1 0.5 ± 0.0d 0.6 ± 0.1d
___________________________________________________________________________________
Female rats
Sodium (mEq/L) 140.7 ± 0.8 139.7 ± 0.8 138.7 ± 0.6 139.7 ± 0.8
Potassium (mEq/L) 9.1 ± 0.4 8.2 ± 0.2 7.8 ± 0.4 9.7 ± 0.5
Bicarbonate (mEq/L) 28.7 ± 0.2 26.0 ± 1.9 24.3 ± 1.5 23.7 ± 0.8
Urea (mg/dl) 32.1 ± 3.1 33.6 ± 3.2 33.4 ± 2.9 32.4 ± 1.6
Creatinine (mg/dl) 0.5 ± 0.0 0.5 ± 0.0 0.6 ± 0.1 0.3 ± 0.0d
___________________________________________________________________________________
d and e represent significant decreases at p<0.05 and p<0.01, respectively, when compared to untreated control (Group I)
values. Group I = 10 ml/kg/day of distilled water, Group II = 20 mg/kg/day of HU, Group III = 100 mg/kg/day of HU,
Group IV = 500 mg/kg/day of HU.
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Table 8: Effect of chronic oral treatment with HU on serum ALT, AST, ALP, TB and CB of treated rats
______________________________________________________________________________
ALT (IU/L) AST (IU/L) ALP (IU/L) TB (mg/dl) CB (mg/dl)
___________________________________________________________________________________
Male
I 30.7 ± 1.1 55.0 ± 4.8 44.7 ± 1.2 0.2 ± 0.1 0.1 ± 0.0
II 37.8 ± 1.8 54.8 ± 4.3 52.2 ± 6.7 0.2 ± 0.0 0.1 ± 0.0
III 37.2 ± 6.4 67.2 ± 5.3 71.2 ± 9.3 0.2 ± 0.1 0.0 ± 0.0
IV 36.2 ± 2.6 66.7 ± 4.9 58.5 ± 8.9 0.2 ± 0.1 0.1 ± 0.0
___________________________________________________________________________________
Female
I 23.7 ± 2.2 59.3 ± 6.5 55.0 ± 7.5 0.3 ± 0.1 0.3 ± 0.1
II 26.3 ± 4.2 64.2 ± 5.4 67.5 ± 8.5 0.2 ± 0.1 0.1 ± 0.0
III 19.0 ± 0.9 68.7 ± 5.6 39.0 ± 2.6 0.1 ± 0.1 0.1 ± 0.0
IV 20.0 ± 4.0 61.8 ± 6.4 51.2 ± 6.9 0.1 ± 0.0 0.1 ± 0.0
___________________________________________________________________________________
Mean ± S.E.M, p>0.05, n = 6; Group I = 10 ml/kg/day of distilled water, Group II = 20 mg/kg/day of HU,
Group III = 100 mg/kg/day of HU, Group IV = 500 mg/kg/day of HU.
Table 9: Effect of toxicity reversibility of HU on serum ALT, AST, ALP, TB and CB of treated rats
__________________________________________________________________________
ALT (IU/L) AST (IU/L) ALP (IU/L) TB (mg/dl) CB (mg/dl)
___________________________________________________________________________________
Male
I 21.7 ± 0.4 62.3 ± 4.3 55.6 ± 16.0 0.5 ± 0.2 0.2 ± 0.1
II 24.0 ± 0.8 64.0 ± 2.3 45.6 ± 10.3 0.5 ± 0.1 0.5 ± 0.1
III 23.8 ± 2.0 65.0 ± 2.5 52.5 ± 4.0 0.6 ± 0.3 0.6 ± 0.3
IV 23.7 ± 2.8 61.8 ± 5.6 58.5 ± 13.6 0.5 ± 0.0 0.3 ± 0.0
___________________________________________________________________________________
Female
I 24.7 ± 2.3 65.0 ± 2.6 36.9 ± 16.8 0.5 ± 0.1 0.5 ± 0.1
II 35.3 ± 1.7 62.7 ± 2.2 28.9 ± 11.0 0.4 ± 0.0 0.3 ± 0.0
III 30.3 ± 4.1 65.0 ± 4.5 28.1 ± 10.6 0.3 ± 0.1 0.2 ± 0.1
IV 27.3 ± 3.2 63.3 ± 2.5 24.1 ± 6.5 0.7 ± 0.1 0.3 ± 0.1
___________________________________________________________________________________
Mean ± S.E.M, p>0.05, n = 6; Group I = 10 ml/kg/day of distilled water, Group II = 20 mg/kg/day of HU, Group
III = 100 mg/kg/day of HU, Group IV = 500 mg/kg/day of HU.
Table 10: Effect of chronic oral treatment of 20-500 mg/kg of HU on serum total protein and albumin
___________________________________________________________________________
Group Treatment total protein albumin
(mg/dl) (mg/dl)
___________________________________________________________________________________
Male
I 10 ml/kg of distilled water 4.8 ± 0.3 3.1 ± 0.2
II 20 mg/kg HU 4.9 ± 0.4 3.3 ± 0.2
III 100 mg/kg HU 4.4 ± 0.5 2.7 ± 0.4
IV 500 mg/kg HU 4.4 ± 0.1 2.7 ± 0.1
___________________________________________________________________________________
Female
I 10 ml/kg of distilled water 6.6 ± 0.3 3.1 ± 0.2
II 20 mg/kg HU 6.8 ± 0.2 3.5 ± 0.2
III 100 mg/kg HU 6.8 ± 0.0 3.6 ± 0.3
IV 500 mg/kg HU 6.6 ± 0.4 3.4 ± 0.4
___________________________________________________________________________________
Mean ± S.E.M, p>0.05, n = 6
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Table 11: Effect of toxicity reversibility test of HU on serum total protein and albumin
__________________________________________________________________________________
Group Treatment total protein albumin
(mg/dl) (mg/dl)
___________________________________________________________________________________
Male
I 10 ml/kg of distilled water 6.7 ± 0.2 4.2 ± 0.3
II 20 mg/kg HU 6.8 ± 0.2 3.5 ± 0.1
III 100 mg/kg HU 7.2 ± 0.5 3.6 ± 0.4
IV 500 mg/kg HU 6.8 ± 0.1 3.6 ± 0.2
___________________________________________________________________________________
Female
I 10 ml/kg of distilled water 7.2 ± 0.0 4.0 ± 0.1
II 20 mg/kg HU 7.0 ± 0.1 3.8 ± 0.2
III 100 mg/kg HU 7.2 ± 0.2 4.1 ± 0.2
IV 500 mg/kg HU 7.6 ± 0.3 4.1 ± 0.0
___________________________________________________________________________________
Mean ± S.E.M, p>0.05, n = 6.
Table 12: Effect of 90-days oral treatment with 20-500 mg/kg of HU on the full blood count of treated male rats
___________________________________________________________________________
I II III IV
___________________________________________________________________________________
RBC (x 106/μl)  08.7 ± 0.1 09.1 ± 0.3 08.6 ± 0.4 09.2 ± 0.2  
Hb (g/dl) 14.4 ± 0.6 15.6 ± 0.2 16.0 ± 0.2b 16.7 ± 0.1b
PCV (%) 49.2 ± 1.4 50.0 ± 0.7 51.6 ± 0.2a 55.9 ± 0.8c
PLT (x103/μl)  672.3 ± 39.8 969.7 ± 28.6a 1291.7 ± 94.9b 1611.8 ± 95.9c
MCV (fl) 56.8 ± 1.1 56.7 ± 0.5 57.1 ± 0.8 59.3 ± 0.4a
MCH (pg) 16.7 ± 0.8 18.1 ± 0.3a 19.3 ± 0.4a 20.0 ± 0.5b
MCHC (g/dl) 29.4 ± 1.3 32.0 ± 0.5a 33.6 ± 0.6b 35.2 ± 1.0 c
TLC (x103/μl)  14.3 ± 1.0 16.9 ± 0.8 17.7 ± 0.7a 19.3 ± 0.4c
lymp (%) 79.4 ± 2.0 82.4 ± 1.6a 88.7 ± 1.6c 90.6 ± 0.9c
Neut (%) 11.4 ± 1.1 11.7 ± 1.2 07.9 ± 0.7d 07.7 ± 0.7d
Gran (%) 09.2 ± 1.0 08.9 ± 0.4 03.5 ± 1.7e 01.7 ± 0.3e
___________________________________________________________________________________
a, b and c represent significant increases while d, e and f represent significant decreases at p<0.05, p<0.01 and p<0.001,
respectively, when compared to Group I values. Group I = 10 ml/kg/day distilled water, Group II = 20 mg/kg/day of HU,
Group III = 100 mg/kg/day of HU , Group IV = 500 mg/kg/day of HU.
Table 13: Effect of 90-days oral treatment with 20-500 mg/kg of HU on the full blood count of treated female
rats
___________________________________________________________________________________
I II III IV
___________________________________________________________________________________
RBC (x 106/μl)  07.2 ± 0.2  07.9 ± 0.4 09.6 ± 0.2c 09.9 ± 0.2c
Hb (g/dl) 12.7 ± 0.7 14.5 ± 0.4a 16.0 ± 0.5c 16.3 ± 0.4c
PCV (%) 40.8 ± 0.8 44.6 ± 1.6a 45.4 ± 1.3a 50.1 ± 1.6b
PLT (x103/μl)  671.0 ± 18.4 1356.0 ± 114.4a 1802.2 ± 38.1b 1878.8 ± 41.9c
MCV (fl) 55.1 ± 0.5 57.8 ± 0.6b 58.3 ± 0.3b 57.9 ± 0.9b
MCH (pg) 18.6 ± 0.2 19.6 ± 0.3b 19.5 ± 1.0b 19.6 ± 0.1b
MCHC (g/dl) 33.7 ± 0.6 34.0 ± 0.5 34.8 ± 0.1b 36.8 ± 0.4c
TLC (x103/μl)  08.2 ± 1.6 10.6 ± 0.3 14.8 ± 0.8b 17.8 ± 0.7c
lymp (%) 77.7 ± 2.7 89.7 ± 1.5a 92.6 ± 0.8c 93.4 ± 0.4c
Neut (%) 11.7 ± 1.0 07.7 ± 0.8f 05.4 ± 0.6f 05.0 ± 0.5f
Gran (%) 10.6 ± 1.7 02.5 ± 0.8f 02.0 ± 0.2f 01.7 ± 0.5f
___________________________________________________________________________________
a, b and c represent significant increases while d, e and f represent significant decreases at p<0.05, p<0.01 and p<0.001,
respectively, when compared to Group I values. Group I = 10 ml/kg/day distilled water, Group II = 20 mg/kg/day HU,
Group III = 100 mg/kg/day HU , Group IV = 500 mg/kg/day HU.
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Table 14: Effect of 14-day toxicity reversibility study of HU on the full blood count of treated male rats
___________________________________________________________________________
I II III IV
___________________________________________________________________________________
RBC (x 106/μl)  08.0 ± 0.1 08.2 ± 0.3 09.0 ± 0.1b 10.0 ± 0.3c
Hb (g/dl) 14.0 ± 0.2 14.3 ± 0.3 15.4 ± 0.3b 16.8 ± 0.2c
PCV (%) 44.4 ± 0.7 45.7 ± 1.1 52.8 ± 1.5a 56.1 ± 1.0a
PLT (x103/μl)  893.7 ± 13.5 955.8 ± 16.6a 1097.2 ± 25.9b 1234.2 ± 07.0c
MCV (fl) 55.8 ± 0.6 58.7 ± 0.5a 60.0 ± 1.1a 65.2 ± 1.1a
MCH (pg) 17.6 ± 0.2 18.2 ± 0.1 18.1 ± 0.4 19.3 ± 0.1a
MCHC (g/dl) 31.5 ± 0.3 31.5 ± 0.6 32.1 ± 0.7 35.9 ± 0.4a
TLC (x103/μl)  07.9 ± 0.7 14.3 ± 1.1 19.2 ± 1.3b 19.5 ± 1.8b
lymp (%) 78.6 ± 1.5 82.3 ± 0.7 84.4 ± 1.4a 89.5 ± 2.0b
Neut (%) 10.2 ± 0.9 11.2 ± 0.5 10.5 ± 0.7 07.1 ± 1.8d
Gran (%) 11.2 ± 0.9 06.9 ± 0.8d 5.2 ± 1.0d 03.5 ± 0.3f
___________________________________________________________________________________
a, b and c represent significant increases while d, e and f represent significant decreases at p<0.05, p<0.01 and p<0.001,
respectively, when compared to Group I values. Group I = 10 ml/kg/day distilled water, Group II = 20 mg/kg/day of HU,
Group III = 100 mg/kg/day of HU , Group IV = 500 mg/kg/day of HU.
Table 15: Effect of 14-day reversibility test of HU on haematological parameters of treated female rats
___________________________________________________________________________
I II III IV
___________________________________________________________________________________
RBC (x 106/μl)  07.6 ± 0.1 08.2 ± 0.1a 10.0 ± 0.2b 11.7 ± 0.1c
Hb (g/dl) 13.2 ± 0.8 15.1 ± 0.2a 16.4 ± 0.2c 16.8 ± 0.1c
PCV (%) 44.5 ± 0.8 47.6 ± 1.0a 53.3 ± 1.2b 57.3 ± 0.4b
PLT (x103/μl)  797.7 ± 79.9 1048.0 ± 55.5a 1175.7 ± 16.4b 1543.0 ± 115.3c
MCV (fl) 58.8 ± 0.5 57.2 ± 0.2 61.5 ± 1.5a 66.1 ± 0.2b
MCH (pg) 17.4 ± 0.9 18.4 ± 0.0a 21.4 ± 0.9b 22.6 ± 0.4b
MCHC (g/dl) 29.6 ± 1.7 32.2 ± 0.2a 34.2 ± 0.5b 41.1 ± 0.1c
TLC (x103/μl)  09.7 ± 0.6 16.4 ± 0.3b 20.1 ± 0.6c 21.3 ± 1.4c
lymp (%) 84.1 ± 3.6 88.9 ± 0.4 92.1 ± 0.6a 92.7 ± 0.6a
Neut (%) 09.5 ± 1.8 05.6 ± 0.1d 05.2 ± 0.7e 05.6 ± 0.6d
Gran (%) 06.3 ± 1.9 04.9 ± 0.5 03.0 ± 0.5 01.8 ± 0.3d
___________________________________________________________________________________
a, b and c represent significant increases at p<0.05, p<0.01 and p<0.001, respectively, while d and e represent significant
decreases at p<0.05 and p<0.01, respectively, when compared to Group I values.
Group I = 10 ml/kg/day distilled water, Group II = 20 mg/kg/day HU, Group III = 100 mg/kg/day HU, Group IV = 500
mg/kg/day HU.
Effect of 90-days oral treatment with 20-500 mg/kg/day of HU and its reversibility test on the relative
organ weights of treated rats
Chronic oral treatment with HU caused a significant (p<0.001) and dose related increases in the relative
weights of liver, stomach, spleen, testis, lungs and heart in the male rats (Tables 2a). At the oral dose of 500
mg/kg/day of HU, there was a significant (p<0.05) reduction in the relative kidney weight when compared to the
100 mg/kg/day of HU-treated values in the male rats (Table 2a). In the female rats, HU treatment caused
significant (p<0.05, p<0.001) and dose-related increases in the relative weights of liver and lungs, a significant
(p<0.01) decrease in the relative kidney weight while causing non-significant (p>0.05) decreases in the relative
weights of stomach and heart (Table 2b). However, following withdrawal of HU treatment for 14 days, there
was no significant (p>0.05) difference in the relative organ weight among the control and treated groups of rats
(Tables 3a and 3b) except in the 100 mg/kg of HU-treated rats that still had significant (p<0.05) increase in the
relative liver weight and significant (p<0.001) decreases in the relative kidney weight (Table 3b). Similarly,
there was still a significant (p<0.01) decrease in the relative kidney weight of 500 mg/kg of HU-treated female
rats after the treatment withdrawal (Table 3b).
Adeneye et al., Afr J Tradit Complement Altern Med. (2010) 7(4):350-369 360
Effect of 90-days oral treatment with 20-500 mg/kg/day of HU and reversibility test on the fasting blood
glucose of treated rats
Prolonged oral treatment with HU caused significant and dose-related (p<0.05, p<0.01 and p<0.001)
reductions in the fasting glucose levels in both sexes of treated rats, with the most significant hypoglycaemic
effect recorded in rats treated with 500 mg/kg/day of HU by reducing the glucose level from 78.7 ± 0.9 mg/dl to
37.0 ± 0.7 mg/dl and 76.5 ± 2.8 mg/dl to 36.2 ± 1.5 mg/dl in the male and female rats, respectively (Table 4).
Despite the withdrawal of oral treatment with HU for 14 days, there was persistence in the significant (p<0.01,
p<0.001) dose-related hypoglycaemic effect at 100 mg/kg and 500 mg/kg of the extract when compared to those
of control and 20 mg/kg of HU-treated groups (Table 5).
Effect of 90-day oral treatment with 20-500 mg/kg/day and toxicity reversibility of HU
on the serum sodium, potassium, bicarbonate, urea and creatinine concentrations of
treated rats
Tables 6 and 7 show the effect of chronic oral treatment with HU and its reversibility on the serum
concentration of sodium, potassium, chloride, bicarbonates, urea and creatinine in the treated rats. HU treatment
produced significant (p<0.05) dose-related reductions in the serum levels of bicarbonate, urea and creatinine
while causing no significant (p>0.05) alterations in the serum levels of sodium and potassium (Table 6). Upon
HU treatment withdrawal, the significant (p<0.05 and p<0.01) dose-dependent reductions in the serum level of
urea still persisted in the male rats while there was no significant (p>0.05) alteration in the level of urea in the
female rats (Table 7). In a similar pattern, HU withdrawal did not significantly (p>0.05) affect the serum levels
of sodium and potassium (Table 7). However, withdrawal of HU resulted in a reversal to about that of the
control values in the serum level of bicarbonates in the female rats while there was a significant (p<0.05)
increase in the serum level of bicarbonates in the male (Table 7).
Effect of 90-day oral treatment with 20-500 mg/kg/day of HU and toxicity reversibility
on the serum alanine transaminase, aspartate transaminase, alkaline phosphatase , total
and conjugated bilirubin concentrations of rats
Chronic treatment with 20-500 mg/kg HU did not significantly (p>0.05) affect the serum concentrations
of ALT, AST, ALP in both sexes of treated rats (Table 8). Similar effect was recorded in the toxicity
reversibility tested rats (Table 9).
Effect of 90-day oral treatment with 20-500 mg/kg/day of HU and its toxicity
reversibility test on the serum total protein and albumin concentrations of treated rats
Chronic oral treatment with 20-500 mg/kg HU did not significantly (p>0.05) alter the serum
concentrations of TP and ALB in both sexes of treated rats (Table 10). Similar effect was recorded in the toxicity
reversibility tested rats (Table 11).
Effect of 90-day oral treatment with 20-500 mg/kg/day of HU on the full blood counts of treated rats
Treatment with HU significantly and dose-dependently increased the haemoglobin concentration (Hb),
packed cell volume (PCV), platelet counts (PLT), mean corpuscular volume (MCV), mean corpuscular
haemoglobin (MCH), mean corpuscular haemoglobin concentration (MCHC), total leucocyte count (TLC), and
lymphocyte while causing significant and dose-related (p<0.05 and p<0.01) reductions in neutrophils and
granulocyte (Tables 12 and 13). These results suggest that HU could have neutropaenic and granulopaenic effect
despites its significant haematopoietic effect.
Effect of 14-days reversibility test of HU on the full blood counts of treated rats
Haematological data in Tables 15 and 16 indicated that despite the withdrawal of HU treatment for 14
days, the significant (p<0.001) elevations in the measured haematological parameters induced by HU treatment
still persisted in both sexes of treated rats. Also, the significant reductions in % Neut and % Gran remained
sustained after 14 days of the extract withdrawal (Tables 14 and 15).
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Figure 1: Graph of log dose vs. probit for the acute oral
toxicity of HU.
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Figure 2: Graph of log dose vs. probit value for the acute
intraperitoneal toxicity of HU.
Figure 3a: A cross-sectional representation of normal rat
liver (Haematoxylin & Eosin stain, x400 magnification)
showing the central hepatic vein and porta triads
surrounded by normal hepatocytes
Figure 3b: A cross-sectional representation of 20 mg/kg
HU-treated rat liver (Haematoxylin & Eosin stain, x400
magnification) showing minimally congested central
hepatic vein with mild lymphocytic infiltration
surrounded by hepatocytes with picnotic nuclei
Figure 3c: A cross-sectional representation of 100 mg/kg
HU-treated liver (Haematoxylin & Eosin stain, x400
magnification) showing moderately congested central
hepatic vein and bile ductal proliferation surrounded by
hepatocytes with picnotic nuclei indicating actively
dividing (mitotic) hepatocytes
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Figure 3d: A cross-sectional representation of 500 mg/kg
HU-treated liver (Haematoxylin & Eosin stain, x400
magnification) showing mild lymphocyte infiltrated porta
triad and bile ductal proliferation surrounded by
hepatocytes with picnotic nuclei indicating actively
dividing hepatocytes
Figure 4a: A cross-sectional representation
(Haematoxylin & Eosin, x400 magnification) showing
normal glomeruli and renal tubules
Figure 4b: A representative section of 20 mg/kg HU-
treated kidney (Haematoxylin & Eosin stain, x400
magnification) showing normal glomeruli and normal
tubules
Figure 4c: A sectional representative of 100 mg/kg
HU-treated rat kidney (Haematoxylin & Eosin stain,
x400 magnification) showing minimal glomerular and
tubular congestion indicating mild glomerulonephritis
Figure 4d: A sectional representative (Haematoxylin &
Eosin stain, x400 magnification) of 500 mg/kg HU-
treated rat kidney showing moderate glomerular and
tubular congestion indicating some degree of
glomerulonephritis
Figure 5a. A sectional representative (Haematoxylin &
Eosin stain, x400 magnification) of the body of normal
rat stomach showing the circular and longitudinal muscle
layers, submucosa and folded mucosa.
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Figure 5b: A sectional representative (Haematoxylin &
Eosin stain, x400 magnification) of the body of 20 mg/kg
HU-treated rat stomach showing mild hypertrophy of the
muscularis propria, submucosa and mucosa.
Figure 5c: A sectional representative (Haematoxylin &
Eosin stain, x400 magnification) of the body of 100
mg/kg HU-treated stomach showing moderate muscularis
propria, submucosal hypertrophy and mucosal
hyperplasia
Figure 5d: A sectional representative (Haematoxylin &
Eosin stain, x400 magnification) of 500 mg/kg HU-
treated stomach showing moderate muscularis propia,
submucosa hypertrophy and mucosal hyperplasia.
Figure 6a: A cross-section of normal rat lungs
(Haematoxylin & Eosin stain, x100 magnification)
showing the bronchioles, pulmonary interstitia and
alveoli
Figure 6b: A cross-section of 20 mg/kg HU-treated rat
lungs (Haematoxylin & Eosin stain, x40 magnification)
showing congested pulmonary vessels, normal
bronchioles and alveolar sacs and mild pulmonary
interstitial proliferation and congestion
Figure 6c: A cross-section of 100 mg/kg HU-treated rat
lungs (Haematoxylin & Eosin stain, x40 magnification)
showing congested bronchioles and pulmonary vessels
and mild pulmonary interstitial proliferation and
congestion but normal alveoli.
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Figure 6d: A cross-section of 500 mg/kg HU-treated rat
lungs (Haematoxylin & Eosin stain, x40 magnification)
showing normal bronchioles and alveoli and moderately
congested pulmonary interstitial and pulmonary vessels.
Figure 7a: A sectional representation of normal rat
spleen (Haematoxylin & Eosin, x40 magnification)
showing normal splenic white pulps
Figure 7b: A sectional representation of 20 mg/kg HU-
treated rat spleen showing proliferation of splenic white
pulp and mildly congested splenic vessels
Figure 7c: A sectional representation of 100 mg/kg HU-
treated rat spleen showing splenic white pulp
proliferation.
Figure 7d: A sectional representation of 500 mg/kg HU-
treated rat spleen showing proliferation of splenic white
pulp and increased vascularization of the splenic red
pulp.
Figure 8a: A cross-section of normal rat testis
(Haematoxylin & Eosin stain, x100 magnification)
showing the tunica albuginae, seminiferous tubules
lined by spermatogenic series, Sertoli and Leydig’s
cells.
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Figure 8b: A cross-section of 20 mg/kg HU-treated rat
testis (x100 magnification) showing seminiferous tubules
lined by mildly dense spermatogenic series, Sertoli and
Leydig’s cells.
Figure 8c: A cross-section of 500 mg/kg HU-treated rat
testis (Haematoxylin & Eosin stain, x100 magnification)
showing seminiferous tubules lined by moderately dense
spermatogenic series, Sertoli and Leydig’s cells.
Effect of 90-days oral treatment with 20-500 mg/kg/day of HU on the histopathology of
selected vital organs of treated rats
Histopathological effect of chronic HU treatment on liver
Figures 3a-3d are representative sections of normal rat liver, 20 mg/kg HU-treated, 100 mg/kg HU-
treated and 500 mg/kg HU-treated rat livers, respectively. Prolonged oral HU treatment produced mild-to-
moderate central hepatic congestion with varying degree of lymphocytic infiltration and hepatocytes with
picnotic nuclei, indicating varying degree of hyperplasia in the hepatocytes of HU-treated livers (Figures 3b-3d).
Histopathological effect of chronic HU treatment on kidneys of rats
Figures 4a-4d are representative sections of normal rat kidney, 20 mg/kg HU-treated, 100 mg/kg HU-
treated and 500 mg/kg HU-treated rat kidneys, respectively. Prolonged HU treatment at 20 mg/kg produced no
obvious histological lesion (Figure 4b). At the oral doses of 100 mg/kg and 500 mg/kg, HU produced mild and
moderate glomerular and tubular congestions indicating glomerulonephritis (Figures 4c-4d).
Histopathological effect of chronic HU treatment on stomach of rats
Figures 5a-5d are representative sections of normal rat stomach, 20 mg/kg HU-treated, 100 mg/kg HU-
treated and 500 mg/kg HU-treated rat stomach, respectively. Prolonged HU treatment at 20 mg/kg produced mild
hypertrophy of the muscularis propria (Figure 5b). At the oral doses of 100 mg/kg and 500 mg/kg, HU produced
moderate muscularis propria, submucosal and mucosal hypertrophy (Figures 5c-5d) when compared to that of
normal rat stomach (Figure 5a).
Histopathological effect of chronic HU treatment on lungs of rats
Figures 6a-6d are representative sections of normal rat lungs, 20 mg/kg HU-treated, 100 mg/kg HU-
treated and 500 mg/kg HU-treated rat lungs, respectively. Prolonged HU treatment at 20 mg/kg produced mild
interstitial proliferation (Figure 6b). At the oral doses of 100 mg/kg and 500 mg/kg, HU produced mild-to-
moderate interstitial proliferation (Figures 6c-6d) when compared to that of normal lungs (Figure 6a).
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Histopathological effect of chronic HU treatment on rat spleen
Prolonged HU treatment caused splenic white and red pulp proliferations in the spleens of treated rats in
a dose-related fashion (Figures 7b-7d) when compared to normal spleen (Figure 7a).
Histopathological effect of chronic HU treatment on rat testes
Prolonged HU treatment at 20 mg/kg produced mild interstitial proliferation (Figure 8b). At the oral
doses of 100 mg/kg and 500 mg/kg, HU produced mild-to-moderate interstitial proliferation (Figures 8c-8d)
when compared to that of normal lungs (Figure 8a).
Histopathological effect of HU treatment on rat heart muscle
Chronic oral treatment with 20-500 mg/kg of HU did not produce any significant histological lesions on
the heart muscles when compared to normal heart muscles.
Effect of 14-days toxicity reversibility on the histopathology of selected vital organs of rats
Histological examination of selected vital organs after 14 days of reversibility test showed no reversal
in the earlier documented histological lesions which were associated with chronic HU treatment.
Discussion
Acute oral toxicity studies showed that HU was orally tolerated for up to 1000 mg/kg body weight.
According to the American Society for Testing and Materials (1987), any chemical substance with LD50 estimate
less than 2000 mg/kg/oral route but greater than 1000 mg/kg/oral could be considered to be slightly toxic,
although Clarke and Clarke (1977) consider any compound with an estimated LD50 equal to or greater than 1000
mg/kg/oral to be safe. Based on the latter recommendation, HU can, thus, be considered relatively safe on acute
exposure. Similarly, the intraperitoneal LD50 of HU was estimated to be 453.9 mg/kg body weight. Substances
with intraperitoneal LD50 value of 500-5000 mg/kg body weight in toxicity rating are classified as being slightly
toxic. Thus, HU can be considered slightly toxic on acute exposure. The acute oral toxicity of HU could be due
to some of the toxic phytocomponents in HU such as tannin and saponin. Saponin has been documented to
induce haemolysis and behavioural toxicity in rats treated with extracts containing high concentration of saponin
(Ajagbonna et al., 1999). It is, therefore, possible that saponin and/or other phytocomponents present in HU to be
responsible for the observed behavioural toxicity of the extract.
In the chronic oral toxicity study, HU at the oral doses of 100 mg/kg and 500 mg/kg produced
significant reductions in the pattern of body weight gain over the 90 days of treatment, indicating the inherent
weight losing potential of the extract. Reductions in body weight gain and internal organ weights are simple but
strong and sensitive indices of toxicity after exposure to toxic substances (Teo et al., 2002). The observed
significant weight loss could have been mediated via appetite inhibiting or lipid lowering effect or other
mechanisms. The presence of saponins in high concentrations has earlier been reported to induce weight loss in
animal exposed to such plants due to its appetite-inhibiting effect (Ajagbonna et al., 1999). Thus, the presence of
this phytocomponent in HU could account for the weight losing effect of HU. In respect of relative organ weight,
HU produced variable effect on the selected organs. In the male and female rats, HU produced increases in the
relative organ weight of all the selected organs except in the relative kidney weight of the female rat where HU
produced significant reduction. The increases in the relative organ weight are strong indications of either organ
hyperplasia/hypertrophy (a physiological enlargement of an organ) or organomegally (a diseased enlargement of
an organ). However, the presence of the histological features of rapid cellular proliferation within the organs
particularly the liver, lungs, stomach and testis, strongly strengthen the former assertion.
Blood is an important index of physiological and pathological status in man and animals and the
parameters usually measured are total red blood counts and its indices, haemoglobin, packed cell volume, total
white blood cell count and its differential counts, platelets count and biochemical parameters such as liver and
renal function tests (Raza et al., 2002; Oduola et al., 2007). The normal range of these parameters can be altered
by the ingestion of some toxic plants (Abatan and Arowolo, 1989; Ajagbonna et al., 1999; Adedapo et al., 2004).
In the present study, HU treatment for 90 days produced significant elevations in the measured haematological
parameters indicating the haematopoietic effect of HU. Thus, the significant elevations in RBC, PCV and Hb
strongly suggest that HU could be useful in the management of anaemia. However, the significant
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thrombocytosis produced by HU treatment suggests that while its haemopoietic effect could be beneficial in the
management of anaemia, the resultant thrombocytosis could invoke predisposition to thrombotic stroke and
ishaemic heart disease. The relative lymphocytosis and the splenic lymphoid proliferation induced by HU
indicate its lymphopoetic effect and possible immunostimulatory potential. This result may be due to the
immune response of the rats to the extract, which led to the mobilization of immune-competent cells. The
implication of this finding is that HU could be immunogenic and this finding appears to be in agreement with
that previously reported in rabbits (Ibeh et al., 2007). On the other hand, the HU-induced neutropaenia and
granulocytopaenia are indicative of its cytotoxic effect on neutrophil and granulocyte lineages. The neutrophils
are the first line of defence in any microbial infection and are often significantly elevated in acute inflammatory
conditions (Guyton and Hall, 2000) while lymphocytes on the other hand produce antibodies that bind to
pathogens to enable their destruction and are more involved in defence against intracellular microbes and tumour
cells (Ganong, 2001). The neutropaenic and granulocytopaenic effects of HU could suggest that the extract could
have damaging effect on this first line of body defence while its lymphocyte-forming effect suggest that HU
could have immune boosting effect. The non reversal in the haematopoietic effect of HU despite the extract
withdrawal indicates that the haematopoietic effect of the extract is long lasting.
The liver is one of the most important organs in the body and is responsible for breaking down all
ingested xenobiotics. Liver function tests conducted through blood assays provide in-depth information about the
state of the liver, describing its functionality (e.g. albumin, total proteins), cellular integrity (e.g.
aminotransaminases) and its link with the biliary tract (e.g. gamma-glutamyl transferase and alkaline
phosphatase) (Boyde and Latner, 1961; Adeoye and Oyedapo, 2004). ALT is the enzyme produced within the
cells of the liver, recording increases in conditions where liver cells have been inflammed or undergone cell
death (Boyde and Latner, 1961; Adeoye and Oyedapo, 2004). As the cells are damaged, the ALT leaks into the
bloodstream leading to a rise in its serum concentrations (Adedapo et al., 2004). However, of these hepatic
enzymes, ALT is the most sensitive and reliable marker of hepatocellular injury since AST is known to be
present in abundance in the cardiac muscles, skeletal muscles, kidneys and testes, and ALP abundant in the
growing bone (Friedman et al., 1996). As a result, any disease state affecting any of these extrahepatic tissues
significantly elevates the serum levels of these enzymes (Friedman, 1996). From the results of chronic oral
toxicity study of HU, serum analyses of the treated rats showed that HU treatment caused no significant
alterations in the serum ALT and AST levels despite elevation in the serum ALP concentration indicating that
HU has no deleterious effect on liver functions. This is a strong indication of the oral safety of HU on liver
function. Similarly, the effect of HU on serum electrolytes, urea and creatinine which are reliable markers of
renal function is also a strong indication of the extract’s safety on the renal function and the possible inherent
nephroprotective potential of the extract despite the minimal and reversible histological lesions associated with
chronic HU use. However, reduction in the serum bicarbonate level indicates the tendency of chronic HU use to
be associated with metabolic acidosis. The presence of flavonoids and alkaloids in HU could account for these
protective effects since these phytocomponents have been documented to confer protection on the liver and
kidneys through prevention of tissue lipid peroxidation which is mediated their anti-oxidant and free-radical
scavenging activities (Fraga et al., 1987; Laughton et al., 1989; Sanz et al., 1994).
Apart from liver enzymes, serum proteins and albumin assays are also used as reliable and sensitive
indicators of liver function status since they are synthesized and metabolized in the liver (Ganong, 2001).
Reductions in their levels are reflective of the hepatocellular damage, particularly in chronic liver disease, while
their levels are elevated during the anabolic phase of protein metabolism, ingestion of high protein diets or in
certain cancerous states like multiple myeloma (Mayne, 1996; Guyton and Hall, 2000). The profound increase in
the serum levels of these proteins couple with the histological lesion of hepatic hyperplasia may indicate the
anabolic effect of HU. The profound increase in the relative testicular weight and the histological evidence of
enhanced spermatogenesis in the testes of HU-treated rat not only strengthen the anabolic theory of HU but also
indicate the fertility-enhancing of the extract in although further studies will be required in this area.
The proliferative effect of HU on the body organs particularly the stomach, liver, lungs, testes and the
spleen is indicative of the potential tumorogenesis of HU, particularly when used on long-term basis. Thus, the
chronic toxicity results indicate that HU should be used with great caution, particularly, when used on long-term
basis.
Results of the oral toxicity reversibility test suggest that despite the withdrawal of HU treatment for 14
days, most of the toxic biological effects and histological lesions induced by HU remain irreversible strongly
indicating that the extract may contain toxic phytocomponents with prolonged half-lives. In the same vein, the
results of the oral toxicity reversibility results indicate that HU should be used with great caution, particularly,
when used on long-term basis as the toxicities emanating from the chronic use of HU may not readily become
reversible on short-term withdrawal.
In conclusion, HU can be considered relatively safe on acute and chronic exposures, although its
prolonged use should be with a great caution as it could have tumour-promoting tendency.
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